Daewoong Pharmaceutical announced that it has signed a contract to export its diabetes treatment Envlo Tab(Enavogliflozin) to eight Central and South American countries. The contract is worth approximately KRW 33.7 billion, bringing the total value, including existing contracts, to approximately KRW 143.3 billion.